Ramon Colomer-Bosch - Publications

[Translated article] Cost-effectiveness of immune checkpoint inhibitors for non-small cell lung cancer in a third level hospital.

Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

Published: January 26, 2026

Cost-effectiveness of immune checkpoint inhibitors for non-small cell lung cancer in a third level hospital.

Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

Published: January 26, 2026

Biomarkers in breast cancer 2024: an updated consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: May 23, 2024

Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome.

Journal: Melanoma research

Published: July 06, 2018

Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 21, 2018

Correction to: Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: June 20, 2018

Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement.

Journal: The oncologist

Published: April 12, 2018

Nivolumab-induced thyroid dysfunction in patients with lung cancer.

Journal: Endocrinologia, diabetes y nutricion

Published: February 20, 2018

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: December 19, 2017

Consensus statement on biomarkers in breast cancer by the Spanish Society of Pathology and the Spanish Society of Medical Oncology

Journal: Revista espanola de patologia : publicacion oficial de la Sociedad Espanola de Anatomia Patologica y de la Sociedad Espanola de Citologia

Published: November 28, 2017

Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: November 03, 2017

In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer.

Journal: Nature communications

Published: September 15, 2017